RxDoctor Payments Data

Darrell Fiske, MD

Rheumatology · Stuart, FLNPI 1831128735

Payments from drug & device makers

$2,179in general payments, 2019–2025

Across 79 payments — averaging $27.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$930
  • Novartis$438
  • UCB, Inc.$266
  • Pfizer$160
  • Johnson & Johnson$126
  • AbbVie$120
  • plus $140 from 2 others

What the payments were for

  • Food & beverage$2,179100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Amgen25$930
Novartis27$438
UCB, Inc.4$266
Pfizer15$160
Johnson & Johnson1$126
AbbVie5$120
GSK1$119
AstraZeneca1$21

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,179 in reported general payments places this provider in the 25th percentile of 453 rheumatology providers in Florida.

See all rheumatology providers in Florida

Medicare billing

Part B allowed, 2024
$3,460,051
Medicare patients
1,151
Services billed
167,242

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Xeljanz XrTofacitinib Citrate45$256,235
OrenciaAbatacept22$134,251
Orencia ClickjectAbatacept17$109,759
EnbrelEtanercept16$93,652
Humira(Cf)Adalimumab13$88,550
Hydroxychloroquine Sulfate233$10,643
MethotrexateMethotrexate Sodium169$6,032
Celecoxib103$4,314
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen158$3,935
Prednisone280$2,922
Duloxetine Hcl70$1,947
Gabapentin108$1,697
Azathioprine17$1,650
Tramadol Hcl130$1,505
Oxycodone Hcl26$1,276

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenEnbrel$930$93,65216 claims
AbbVieHumira(Cf)$120$88,55013 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 25th percentile of 453 rheumatology providers in Florida.

Other rheumatology in Stuart

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →